Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL271380 | 1.00 | — | — | |
| SCHEMBL303005 | 1.00 | NAAA (0.52) | NAAATSHRTHRBMEN1KMT2A | |
| SCHEMBL4604995 | 1.00 | NAAA (0.52) | NAAATSHRTHRBMEN1KMT2A | |
| SCHEMBL303477 | 1.00 | NAAA (0.52) | NAAATSHRTHRBMEN1KMT2A | |
| SCHEMBL3801573 | 1.00 | NAAA (0.52) | NAAATSHRTHRBMEN1KMT2A | |
| SCHEMBL2536851 | 1.00 | NAAA (0.52) | NAAATSHRTHRBMEN1KMT2A | |
| SCHEMBL56917 | 0.97 | — | — | |
| SCHEMBL9848564 | 0.94 | NAAA (0.52) | NAAATSHRTHRBMEN1KMT2A | |
| SCHEMBL277225 | 0.90 | TSHR (0.61) | NAAATSHRTHRBMEN1KMT2A | |
| SCHEMBL9206028 | 0.90 | TSHR (0.61) | NAAATSHRTHRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602955-B | Photocuring method, compound used in photocuring method, and composition | 富士胶片和光纯药株式会社 | 2021-08-06 | — | — | CN | disclosed |
| CN-107848963-B | Acid-resistant alkali-producing agent and/or radical-producing agent, and curable resin composition containing same | 富士胶片和光纯药株式会社 | 2020-11-03 | — | — | CN | disclosed |
| CN-110678500-A | Photo-or thermosetting method and curable resin composition | 富士胶片和光纯药株式会社 | 2020-01-10 | — | — | CN | disclosed |
| EP-2924044-B1 | PLATINUM COMPOUND OF MALONIC ACID DERIVATIVE HAVING LEAVING GROUP CONTAINING AMINO OR ALKYLAMINO | BEIJING SHUOBAI PHARMACEUTICAL CO LTD (CN) | 2018-10-31 | — | — | EP | disclosed |
| US-9871216-B2 | Organic photoelectric conversion element and organic solar cell using the same | Konica Minolta, Inc. (JP) | 2018-01-16 | — | — | US | disclosed |
| US-9725477-B2 | Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino | BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD (CN) | 2017-08-08 | — | — | US | disclosed |
| EP-2744005-B1 | ORGANIC PHOTOELECTRIC CONVERSION ELEMENT AND ORGANIC SOLAR CELL EMPLOYING SAME | KONICA MINOLTA INC (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20150368281-A1 | Platinum Compounds Of Malonic Acid Derivative Having Leaving Group Containing Amino Or Alkylamino | BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD (CN) | 2015-12-24 | — | — | US | disclosed |
| EP-2924044-A1 | PLATINUM COMPOUND OF MALONIC ACID DERIVATIVE HAVING LEAVING GROUP CONTAINING AMINO OR ALKYLAMINO | BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT, CO., LTD (CN) | 2015-09-30 | — | — | EP | disclosed |
| EP-1866165-B1 | INKJET-RECORDING INK SET, INKJET-RECORDING INK AND INKJET IMAGE-RECORDING METHOD | FUJIFILM CORP (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-5688823-A | ANTILIPEMIC AGENTS, ANTIGLYCEMIC AGENTS, OBESITY, GLUCOSE TOLERANCE INSUFFICIENCY, INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1997-11-18 | — | — | US | disclosed |
| US-5578620-A | TREATMENT OF DIABETES AND HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1996-11-26 | — | — | US | disclosed |
| EP-0678511-A2 | Thiazolidine and oxazolidine derivatives, their preparation and their medical use | SANKYO COMPANY LIMITED (JP) | 1995-10-25 | — | — | EP | disclosed |
| EP-0338808-B1 | Alkyl salicylate resin for carbonless copy paper and imaging use | SCHENECTADY INT INC (US) | 1995-08-23 | — | — | EP | disclosed |
| US-5017546-A | Metallized phenolic resins | SCHENECTADY INTERNATIONAL, INC. | 1991-05-21 | — | — | US | disclosed |
| EP-0338808-A2 | Alkyl salicylate resin for carbonless copy paper and imaging use | SCHENECTADY INTERNATIONAL, INC. (US) | 1989-10-25 | — | — | EP | disclosed |
| US-4562068-A | Sebosuppressive cosmetic preparations containing aryloxobutenoic acid derivatives | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1985-12-31 | — | — | US | disclosed |
| US-4496447-A | PHOTOPOLYMERIZATION OF UNSATURATED COMPOUNDS AND FOR CURING PRINTING INKS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1985-01-29 | — | — | US | disclosed |
| US-4374984-A | Aromatic-aliphatic ketones useful as photoinitiators | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-02-22 | — | — | US | disclosed |
| US-4234212-A | POLYVALENT METAL AROMATIC CARBOXYLATE, METHYLATED MELAMINE RESIN, WATER SOLUBLE POLYMER | FUJI PHOTO FILM CO., LTD. (JP) | 1980-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368281-A1 | Platinum Compounds Of Malonic Acid Derivative Having Leaving Group Containing Amino Or Alkylamino | SLC7A1, ME3, SLC7A5 | NAAA 2341/4885TSHR 4501/4885THRB 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.